Intel Corporation v. CPM United Kingdom Ltd.

Global Silicon Photonics Global Market Report 2023: Surging Utilization of Silicon Photonics Technology in Short-Reach Communication Presents Opportunities

Retrieved on: 
Friday, May 19, 2023
Component, Communication, Data-rate units, Data, Wireless, IP, USD, SATCOM, Government, Intel, QSFP28, Investment, Growth, Silicon, Transceiver, Intel Corporation v. CPM United Kingdom Ltd., Silicon photonics, Microscope, Telecommunications, Waveguide, Geography

Increasing government and stakeholder funding, growing deployment of 5G networks, emerging applications of silicon photonics, and surging utilization of silicon photonics technology in short-reach communication provide lucrative opportunities to the silicon photonics market.

Key Points: 
  • Increasing government and stakeholder funding, growing deployment of 5G networks, emerging applications of silicon photonics, and surging utilization of silicon photonics technology in short-reach communication provide lucrative opportunities to the silicon photonics market.
  • The Transceivers segment is expected to dominate the silicon photonics market during the forecast period.
  • Technological advancements in silicon photonics have made it possible to transfer data at a speed of up to 800 Gbps.
  • Many technology giants plan to have their data centers in the country, providing an excellent opportunity for the silicon photonics market in this region.

Chain Pharmaceuticals GmbH Announces Its Phytocannabinoid Drug Discovery Platform

Retrieved on: 
Tuesday, November 15, 2022
Curia, Intel Corporation v. CPM United Kingdom Ltd., Union, AI, Pharmacology, Doctor of Philosophy, Machine learning, EMA, Artificial intelligence, Algorithm, Patient, Intel, CIO, Cannabis, GDPR, PAREXEL, Medicine, CHMP, Drug development, Research, Charles University, Cannabinoid, AM, Intelligence, Entrepreneurship, Health, Drug discovery, Acquisition, Pharmaceutical industry, Medical device, MD, Ematheudes neurias

FRANKFURT AM MAIN, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Dr. Pierre Debs, Ph.D. announced today the launch of Chain Pharmaceuticals GmbH, a phytocannabinoid drug discovery company leveraging machine learning and real world medical data in the development of clinically proven plant-based medicines for market authorization.

Key Points: 
  • FRANKFURT AM MAIN, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Dr. Pierre Debs, Ph.D. announced today the launch of Chain Pharmaceuticals GmbH, a phytocannabinoid drug discovery company leveraging machine learning and real world medical data in the development of clinically proven plant-based medicines for market authorization.
  • Clinically proven market authorized medications are sine qua non for long-term demands of all stake-holders throughout European healthcare systems, explains Dr. Pierre Debs, Founder and Chief Executive Officer of Chain Pharmaceuticals GmbH.
  • Chain Pharmaceuticals patient data-gathering app, HealChain, is designed with Innoplexus app and its capabilities of data extraction with AI algorithms.
  • Chain Pharmaceuticals GmbH is a German-based drug discovery company using real world data, machine-learning and artificial intelligence to rapidly design and execute clinical trials leading to market-authorized phytocannabinoid products.

QCT Collaborates with Samsung and Intel to Lead Transition to PCIe Gen5 with Next-Generation Servers and SSDs

Retrieved on: 
Tuesday, July 26, 2022
Hardware, Data Management, Consumer Electronics, Technology, Software, Quanta, Cloud, DDR5, 3D XPoint, Industry, Twitter, IOPS, Intel, Electronics, Solution, Intel Corporation v. CPM United Kingdom Ltd., General manager, QCT, Engineering, Multimedia, QCT (Quanta Cloud Technology), News, HCI, Facebook, EVP, Technology, SSD, SVP, NVM Express, Efficiency, Samsung, Growth, Solid-state drive, Samsung Electronics, Video game console, Computer data storage, Semiconductor, Architecture

Quanta Cloud Technology (QCT), a global data center solution provider, today announced the worlds first validation of Samsung PM1743 PCIe Gen5 SSDs in their new all-flash NVMe servers powered by 4th Gen Intel Xeon Scalable processors.

Key Points: 
  • Quanta Cloud Technology (QCT), a global data center solution provider, today announced the worlds first validation of Samsung PM1743 PCIe Gen5 SSDs in their new all-flash NVMe servers powered by 4th Gen Intel Xeon Scalable processors.
  • Furthermore, these unique solutions provide flexibility for modern data center needs ranging from low latency applications to data processing, and hyper-converged infrastructures (HCI).
  • QCT worked closely with Samsung to test and be among the first to validate Samsungs PM1743 PCIe Gen5 SSDs on our Intel powered systems, said Mike Yang, President of QCT.
  • Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.

Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors

Retrieved on: 
Tuesday, July 5, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Diamond, Board of directors, International relations, Control, Cayman, COVID-19, Cytokine, Immune system, Marketing, Wheaton College, Zhejiang University, The Advisory Board Company, Thunderbird School of Global Management, MBA, International Management Institute, New Delhi, Association of British HealthTech Industries, Therapy, NYSE, Advisory board, SEC, Chemistry, Global, Forward-looking statement, MS, CEO, Wuxi, Goal, Health care, Carnegie Mellon University, Celebrity board director, Bristol Myers Squibb, Private Securities Litigation Reform Act, Board, Intel, Intel Corporation v. CPM United Kingdom Ltd., Physics, EPB, Annual report, WuXi Biologics, Association, U.S. Securities and Exchange Commission, Thunderbird, Clinical trial, Kate, Therapure BioPharma Inc, Safety, Director, Pharmaceutical industry, Pharma

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointments of Edward Hu and Kate Hermans to its Board of Directors.

Key Points: 
  • Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointments of Edward Hu and Kate Hermans to its Board of Directors.
  • I am delighted to welcome both Edward and Kate to Ambrxs Board, said Feng Tian, Ph.
  • Edward Hu has more than 25 years experience in the pharmaceutical industry.
  • Ms. Hermans is a Board Director on the Advisory Board of Clue and serves on the Board of Mid-Atlantic Diamond Ventures.

Platform9 closes $26 Million Financing led by Celesta Capital

Retrieved on: 
Tuesday, June 14, 2022
Cloud, Life, DIY, Treasurer, SAP, CFO, Apple, Cisco Systems, Oracle, Insurance, Mergers & Acquisitions, Intel Capital, Customer satisfaction, Intel Corporation v. CPM United Kingdom Ltd., Juniper, Bhaskar, Software, Yoy, GTM, ARR, Semiconductor, CEO, Mergers and acquisitions, Capital, Solution, Investment, Portal Software, Intelligence, Celesta, Intel, Growth, Risk, Technology, Kingfisher plc, Industry, Cloudera, Flex, Element, Software as a service, CRO, Mavenir, Management, Bank, Video game console, Financial services, Redfin, Kubernetes

MOUNTAIN VIEW, Calif., June 14, 2022 /PRNewswire/ -- Platform9, the Open Distributed Cloud company, today announced that it has closed $26 million financing led by Celesta Capital, with participation from Cota Capital, NGP Capital, and other investors. This financing round comes on the back of three consecutive years of 100% growth in annual recurring revenue (ARR) for SaaS Kubernetes, led by enterprise interest in cloud-native distributed clouds. 

Key Points: 
  • MOUNTAIN VIEW, Calif., June 14, 2022 /PRNewswire/ -- Platform9 , the Open Distributed Cloud company, today announced that it has closed $26 million financing led by Celesta Capital , with participation from Cota Capital , NGP Capital , and other investors.
  • In addition to the financing, the company announced two significant appointments to the executive team to help scale the company rapidly.
  • Celesta Capital is a leading deep technology venture capital firm that leverages synergies between leading centers of innovation in the US, India, and Israel to create globally impactful enterprises.
  • Cota delivers "knowledge capital," a differentiated combination of financial capital, deep operational expertise, know-how, impactful and data-driven market insights and intelligence, and a vast industry network.

Cepton, Inc. Announces General Counsel Appointment

Retrieved on: 
Monday, April 18, 2022
Technology, Automotive, General Automotive, Automotive Manufacturing, Manufacturing, Software, Performance & Special Interest, Data Management, Fleet Management, CEO, Paul's walk, Latham & Watkins, Economics, OEM, MI, Twitter, Transport, CA, General counsel, Tier, University of California, Davis, LinkedIn, Wilson Sonsini Goodrich & Rosati, Growth, Ultra, Â, Solution, Intel Corporation v. CPM United Kingdom Ltd., Law, General officer, ADAS, Original equipment manufacturer, IP, Silicon, City, Industry, University, Intel, Perception, Management, Public relations, Metro Detroit

Cepton, Inc. (Cepton) (Nasdaq: CPTN), a Silicon Valley innovator and leader in high-performance MMT lidar solutions , today announced the appointment of Paul Anawalt to the newly created position of General Counsel, effective today.

Key Points: 
  • Cepton, Inc. (Cepton) (Nasdaq: CPTN), a Silicon Valley innovator and leader in high-performance MMT lidar solutions , today announced the appointment of Paul Anawalt to the newly created position of General Counsel, effective today.
  • Dr. Jun Pei, Ceptons Co-Founder, Chairman and CEO said: On behalf of the company I would like to welcome Paul to Cepton.
  • As our General Counsel, Paul's work will help Cepton accelerate our commercial success and help shape the lidar industry.
  • Cepton General Counsel Paul Anawalt said: I am grateful for the opportunity to lead the legal organization of Cepton and excited to help strengthen Ceptons business and develop our legal strategy to support our planned growth.

Intel Names David Zinsner Executive Vice President and Chief Financial Officer

Retrieved on: 
Monday, January 10, 2022
Software, Networks, Internet, Hardware, Data Management, Consumer Electronics, Technology, Semiconductor, IDM, Credit, Semiconductor, Technology, Treasury, Accounting, Name, Intel, INTC, Intel Corporation v. CPM United Kingdom Ltd., Micrometre, Analog Devices, Leadership, Â, Micron Technology, Intelligence, Nasdaq, Industry, Vanderbilt University, Culture, CFO, Multimedia, Carnegie Mellon University, Management

Intel Corporation today announced that David Zinsner has been appointed as the companys executive vice president and chief financial officer (CFO), effective Jan. 17, 2022.

Key Points: 
  • Intel Corporation today announced that David Zinsner has been appointed as the companys executive vice president and chief financial officer (CFO), effective Jan. 17, 2022.
  • Zinsner has more than 20 years of financial and operational experience in semiconductors and manufacturing, including most recently as executive vice president and CFO at Micron Technology, Inc.
  • View the full release here: https://www.businesswire.com/news/home/20220110005917/en/
    David Zinsner has been appointed as Intel Corporation's executive vice president and chief financial officer, effective Jan. 17, 2022.
  • Prior to his role at Micron, Zinsner served as president and chief operating officer at Affirmed Networks.